Renalase in Haemodialysis Patients with Chronic Kidney Disease

Abstract

Chronic kidney disease (CKD) is an inflammatory disease leading to kidney insufficiency and uremia. Renalase is a novel flavoprotein with enzymatic activities. Previous studies have shown that chronic kidney disease may influence renalase serum levels. Renalase metabolises catecholamines and therefore may be involved in the pathogenesis of hypertension and other diseases of the circulatory system. In this study, we examined renalase levels in serum, erythrocytes and urine from haemodialysis CKD patients. The study enrolled 77 haemodialysis CKD patients and 30 healthy subjects with normal kidney function as the control group. Renalase serum and urine concentrations in CKD patients were significantly increased when compared with control subjects (185.5 ± 64.3 vs. 19.6 ± 5.0 ng/mL; p < 0.00001 and 207.1 ± 60.5 vs. 141.6 ± 41.3 ng/mL; p = 0.00040, respectively). In contrast, renalase levels in erythrocytes were significantly lower in CKD patients when compared with control subjects (176.5 ± 60.9 vs. 233.2 ± 83.1 ng/mL; p = 0.00096). Plasma levels of dopamine, adrenaline and noradrenaline were also significantly lower in CKD patients when compared with controls. Conclusions: Increased serum and urine concentrations of renalase in haemodialysis CKD patients are likely related to compensatory production in extrarenal organs as a result of changes in the cardiovascular system and hypertension. The decreased plasma concentrations of catecholamines may be due to their increased degradation by plasma renalase. Decreased renalase levels in erythrocytes may be probably due to lower renalase synthesis by the kidneys in CKD. The results indicate the presence of renalase in erythrocytes.

Assessment of blood serum renalase in end stage kidney failure patient in Babylon city

“…GFR capacity is muddled by the hidden creatinine component, which varies from person to person over time. Renalase levels are much lower in patients with chronic kidney disease (CKD), which correlates with higher levels of endotelin, a ormone linked to the etiology of cardiovascular disease (8).…”

The Effect of Bilateral Nephrectomy on Renalase and Catecholamines in Hemodialysis Patients

“…So far, only a few studies have examined renalase in patients after nephrectomy. To our knowledge, this constitutes the first study examining the concentrations of renalase in erythrocytes in these patients [ 24 , 25 ].…”

“…This study included the following participants: 27 Caucasian hemodialysis patients (15 males and 12 females, mean age 52.5 ± 13.5 years, mean dialysis duration 769 ± 547 days) who were post-bilateral nephrectomy; 46 hemodialysis patients without nephrectomy, but with chronic kidney disease and anuria (30 males and 16 females), with a mean age of 66.2 ± 16.8 years and mean dialysis duration of 910 ± 729 days; and 30 healthy subjects with normal kidney function (normal GFR values and normal creatinine serum concentrations; (15 males and 15 females) and a mean age of 57.4 ± 18.5 years [ 24 , 25 ]. The causes of bilateral nephrectomy were polycystic kidney disease in 10 patients, glomerular kidney disease in 1 patient, neoplasmatic diseases in 8 patients, birth defects in 4 patients and other causes in 4 patients.…”

“…Nephrectomy and hemodialysis (HD) treatment may alter the production and metabolism of renalase [ 22 , 23 ]. In our previous studies, we examined renalase concentrations in patients with chronic kidney diseases with residual kidney function and on hemodialysis [ 24 , 25 ]. Our results indicated that renalse levels were increased in serum and decreased in erythrocytes.…”

Renalase – a new instrument in multicomponent heart failure assessment

“…Более того, детализированные протоколы многоцентровых проспективных исследований продемонстрировали, что функциональный полиморфизм этого гена был ассоциирован с гипертрофией миокарда у больных со стенозом устья аорты, артериальной гипертонией, метаболическим синдромом, нестабильной стенокардией и стабильными формами ишемической болезни сердца, а также у пациентов, получающих заместительную почечную терапию [9]. Реналаза была предложена в качестве прогностического биомаркера ишемии у пациентов с коронарной микрососудистой дисфункцией, а также в качестве предиктора клинически значимого прогрессирования хронической болезни почек у пациентов с сердечно-сосудистыми заболеваниями [9,12]. В доступной нам литературе мы нашли небольшое количество работ по ее изучению у пациентов с СН.…”